Abstract:Chimeric antigen receptor (CAR) T cell show promise in cancer treatments, but their mechanism of action is not well understood. Decoding the mechanisms used by individual T cells can help improve the efficacy of T cells while also identifying mechanisms of T cell failure leading to tumor escape. Here, we used a suite of assays including dynamic single-cell imaging of cell-cell interactions, dynamic imaging of fluorescent reporters to directly track cytotoxin activity in tumor cells, and scRNA-seq on patient infusion products to investigate the cytotoxic mechanisms used by individual CAR T cells in killing tumor cells. We show that surprisingly, overexpression of the Granzyme B (GZMB) inhibitor, protease inhibitor-9 (PI9), does not alter the cytotoxicity mediated by CD19-specific CAR T cells against either the leukemic cell line, NALM6; or the ovarian cancer cell line, SkOV3-CD19. We designed and validated reporters to directly assay T cell delivered GZMB activity in tumor cells and confirmed that while PI9 overexpression inhibits GZMB activity at the molecular level, this is not sufficient to impact the kinetics or magnitude of killing mediated by the CAR T cells. Altering cytotoxicity mediated by CAR T cells required combined inhibition of multiple pathways that are tumor cell specific: (a) B-cell lines like NALM6, Raji and Daudi were sensitive to combined GZMB and granzyme A (GZMA) inhibition; whereas (b) solid tumor targets like SkOV3-CD19 and A375-CD19 (melanoma) were sensitive to combined GZMB and Fas ligand inhibition. We realized the translational relevance of these findings by examining the scRNA-seq profiles of Tisa-cel and Axi-cel infusion products and show a significant correlation between GZMB and GZMA expression at the single-cell level in a T cell subset-dependent manner. Our findings highlight the importance of the redundancy in killing mechanisms of CAR T cells and how this redundancy is important for efficacious T cells.

Redirecting Killer T Cells Through Incorporation of Azido Sugars for Tethering Ligands

Chemical Remodeling Cell Surface Glycans for Immunotargeting of Tumor Cells

A Chimera Antigen Receptor Containing TLR4 Signaling Domain Enhances CAR-iMACs Polarization and Potency against Solid Tumors

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

Refining chimeric antigen receptors via barcoded protein domain combination pooled screening

Directing CAR NK Cells via the Metabolic Incorporation of CAR Ligands into Malignant Cell Glycans

Avidity‐Based Selection of Tissue‐Specific CAR‐T Cells from a Combinatorial Cellular Library of CARs

Nanobody-based CAR T cells targeting intracellular tumor antigens

Click CAR-T cell engineering for robustly boosting cell immunotherapy in blood and subcutaneous xenograft tumor

Improved Antitumor Efficacy of Chimeric Antigen Receptor T Cells that Secrete Single-Domain Antibody Fragments

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells

A Customizable Platform to Integrate CAR and Conditional Expression of Immunotherapeutics in T Cells

Sensitive manipulation of CAR T cell activity using a chimeric endocytosing receptor

Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition

Optimization of T Cell Redirecting Strategies: Obtaining Inspirations from Natural Process of T Cell Activation

Glyco-binding domain chimeric antigen receptors as a new option for cancer immunotherapy

Design of diversified chimeric antigen receptors through rational module recombination

Genetic retargeting of E3 ligases to enhance CAR T cell therapy

Antibody-targeted T cells and natural killer cells for cancer immunotherapy

DNA origami assembled spheroid for evaluating cytotoxicity and infiltration of chimeric antigen receptor macrophage (CAR-M)

Versatile strategy for controlling the specificity and activity of engineered T cells